When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.

Read More

Related Articles

Read More

Related Articles

They then conducted another test to see if they could actually prevent the virus from entering cells.

Among the first 20 or so antibodies tested, four were able to block viral entry and of those, two were "exceedingly good" at doing so, Zhang said.

The team is now focused on identifying the most powerful antibodies and possibly combining them to mitigate the risk of the new coronavirus mutating.

If all goes well, interested developers could mass-produce them for testing, first on animals and eventually on humans.

The group has partnered with a Sino-U.S. biotech firm, Brii Biosciences, in an effort "to advance multiple candidates for prophylactic and therapeutic intervention".

”The importance of antibodies has been proven in the world of medicine for decades now," Zhang said.

He continued: ”They can be used to treat cancer, autoimmune diseases and infectious diseases."

The antibodies are not a vaccine but could potentially be given to at-risk people with the aim of preventing them from contracting Covid-19.

Normally it takes around two years for a drug even to get close to approval for use on patients, but the Covid-19 pandemic means things are moving faster, he said, with steps that would previously be taken sequentially now being done in parallel.

Zhang, who posted the findings online, hopes the antibodies can be tested on humans in six months. If they are found to be effective in trials, the actual use for treatment would take longer.

It is hoped the first trials will happen this year (Image: Getty Images)

Read More

Related Articles

"There's a number of steps which will now need to be followed before it could be used as a treatment for coronavirus patients," Hong Kong University infectious disease specialist

Ben Cowling said when the finding was described to him.

"But it's really exciting to find these potential treatments, and then have a chance to test them out. Because if we can find more candidates, then eventually we'll have better treatment," Cowling said.